Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.

@article{Cantley2011InhibitorsOH,
  title={Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.},
  author={Melissa D. Cantley and David P. Fairlie and Peter Mark Bartold and Kim Drummond Rainsford and Giang Thanh Huong Le and Andrew J. Lucke and Christopher A. Holding and David R. Haynes},
  journal={Journal of cellular physiology},
  year={2011},
  volume={226 12},
  pages={
          3233-41
        }
}
Histone deacetylase inhibitors (HDACi) suppress cancer cell growth, inflammation, and bone resorption. The aim of this study was to determine the effect of inhibitors of different HDAC classes on human osteoclast activity in vitro. Human osteoclasts generated from blood mononuclear cells stimulated with receptor activator of nuclear factor kappa B (RANK) ligand were treated with a novel compound targeting classes I and II HDACs (1179.4b), MS-275 (targets class I HDACs), 2664.12 (targets class… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats

  • Pain research & management
  • 2019
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 55 REFERENCES

Inhibitors selective for HDAC6 in enzymes and cells.

  • Bioorganic & medicinal chemistry letters
  • 2010
VIEW 3 EXCERPTS

Gene expression profiling in Paget's disease of bone: upregulation of interferon signaling pathways in pagetic monocytes and lymphocytes.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2007
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

FDA clears Amgen ’ s bone strengthening drug Prolia

M Perrone
  • 2010
VIEW 1 EXCERPT

Osteoclast-osteoblast communication.

  • Archives of biochemistry and biophysics
  • 2008
VIEW 1 EXCERPT